for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding Ltd.

ROG.S

Latest Trade

342.25CHF

Change

-1.05(-0.31%)

Volume

87,803

Today's Range

340.30

 - 

343.30

52 Week Range

255.95

 - 

344.75

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
343.30
Open
340.75
Volume
87,803
3M AVG Volume
0.62
Today's High
343.30
Today's Low
340.30
52 Week High
344.75
52 Week Low
255.95
Shares Out (MIL)
855.76
Market Cap (MIL)
293,084.80
Forward P/E
--
Dividend (Yield %)
--

Next Event

Roche Holding AG Virtual Early Drug Development gRED Call

Latest Developments

More

Roche's Tecentriq wins first approval in China for lung cancer

Roche Gives Update On Tecentriq For Treatment Of Liver Cancer

Roche Receives Positive CHMP Opinion For Lymphocytic Leukaemia Drug

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Roche Holding Ltd.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Contact Info

Grenzacherstr. 124

+41.9.732354295

http://www.roche.com

Executive Leadership

Severin Schwan

Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director

Christoph Franz

Non-Executive Independent Chairman of the Board

Fritz Gerber

Honorary Chairman of the Board

Andre S. Hoffmann

Non-Executive Independent Vice Chairman of the Board

Alan Hippe

Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer

Key Stats

2.28 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

53.3K

2018

56.8K

2019

61.5K

2020(E)

63.4K
EPS (CHF)

2017

15.340

2018

18.140

2019

20.160

2020(E)

20.462
Price To Earnings (TTM)
21.52
Price To Sales (TTM)
4.77
Price To Book (MRQ)
8.79
Price To Cash Flow (TTM)
15.93
Total Debt To Equity (MRQ)
43.86
LT Debt To Equity (MRQ)
38.68
Return on Investment (TTM)
25.98
Return on Equity (TTM)
17.46

Latest News

Latest News

BRIEF-Roche's Tecentriq wins first approval in China for lung cancer

* CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTS APPROVAL OF ROCHE'S TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PEOPLE WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

BRIEF-Roche Gives Update On Tecentriq For Treatment Of Liver Cancer

* ROCHE TO PRESENT NEW DATA ON TECENTRIQ IN COMBINATION WITH AVASTIN THAT SHOWS IMPROVEMENT IN OVERALL SURVIVAL FOR CHINESE PATIENTS WITH THE MOST COMMON FORM OF LIVER CANCER

BRIEF-Roche's risdiplam boosted motor function in older SMA patients - study

* ROCHE'S RISDIPLAM SHOWED SIGNIFICANT IMPROVEMENT IN MOTOR FUNCTION IN PEOPLE AGED 2-25 WITH TYPE 2 OR 3 SPINAL MUSCULAR ATROPHY

BRIEF-Roche Receives Positive CHMP Opinion For Lymphocytic Leukaemia Drug

* ROCHE ANNOUNCES CHMP RECOMMENDATION FOR EU APPROVAL OF VENCLYXTO PLUS GAZYVARO FOR PEOPLE WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

BRIEF-Roche CFO Says With Spark Acquisition Completed, Company Is Ready For Further Acquisitions

* ROCHE CFO SAYS WITH SPARK ACQUISITION COMPLETED, COMPANY IS READY FOR FURTHER ACQUISITIONS Source text for Eikon: Further company coverage: (Reporting by John Miller)

BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth

* ROCHE CEO SAYS IMPACT OF BIOSIMILARS ON HERCEPTIN, RITUXAN IS "WASHING OUT" IN EUROPE, WHERE ROCHE IS RETURNING TO GROWTH, SEES AVASTIN BIOSIMILARS HIT STARTING LATER THIS YEAR

BRIEF-Roche Says European Commission Has Approved Lymphoma Treatment Polivy

* EUROPEAN COMMISSION APPROVES ROCHE'S POLIVY FOR PEOPLE WITH PREVIOUSLY TREATED AGGRESSIVE LYMPHOMA Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Amunix Says Has Provided Technology License To F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc

* AMUNIX PHARMACEUTICALS, INC. - HAS PROVIDED TECHNOLOGY LICENSE TO F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

BRIEF-EU approves Roche's Kadcyla in early breast cancer

* EUROPEAN COMMISSION APPROVES ROCHE’S KADCYLA FOR THE ADJUVANT TREATMENT OF PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT TREATMENT Further company coverage: (Reporting by Silke Koltrowitz)

BRIEF-Roche, Spark Therapeutics Announce Completion Of Acquisition

* ROCHE CONCLUDES ACQUISITION OF SPARK THERAPEUTICS, INC. TO STRENGTHEN PRESENCE IN GENE THERAPY

Roche has 60.4% of Spark, plans to wrap up takeover on Tuesday

Swiss drugmaker Roche Holding <ROG.S> plans to complete on Tuesday its $4.3 billion takeover of Spark Therapeutics <ONCE.O>, it said, after winning U.S. regulatory approval for the long-delayed deal.

BRIEF-Roche, Spark Therapeutics Announce Clearance By Uk Authority

* ROCHE AND SPARK THERAPEUTICS, INC. ANNOUNCE UNCONDITIONAL CLEARANCE BY UK COMPETITION AND MARKETS AUTHORITY

BRIEF-Roche Publishes New Positive Phase 3 Results For Tecentriq

* POSITIVE PHASE III STUDY RESULTS FOR TECENTRIQ PLUS COTELLIC AND ZELBORAF IN PEOPLE WITH PREVIOUSLY UNTREATED BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA

BRIEF-Roche And Fortelinea To Co-Market Software Solutions In U.S.

* ROCHE - AGREEMENT ALLOWS FOR LINKING OF ROCHE'S VENTANA CONNECT MIDDLEWARE WITH FORTELINEA'S PRIMA LAB TRACKING AND MANAGEMENT SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Roche Gives Update On Perjeta Breast Cancer Treatment

* APHINITY SIX-YEAR RESULTS STRENGTHEN EVIDENCE OF CLINICAL BENEFIT WITH ROCHE’S PERJETA-BASED REGIMEN

BRIEF-5th Generation Of Roche’s Founder’s Family Runs For Board Of Directors Seat

* CHANGES IN THE BOARD OF DIRECTORS AND THE CORPORATE EXECUTIVE COMMITTEE OF ROCHE

BRIEF-FDA Grants Priority Review To Roche’S Risdiplam For Spinal Muscular Atrophy

* FDA GRANTS PRIORITY REVIEW TO ROCHE'S RISDIPLAM FOR SPINAL MUSCULAR ATROPHY

BRIEF-Roche To Present Data For 7 Approved And Investigational Medicines Across Multiple Types Of Breast Cancer

* ROCHE TO PRESENT NEW AND UPDATED DATA FOR SEVEN APPROVED AND INVESTIGATIONAL MEDICINES ACROSS MULTIPLE TYPES OF BREAST CANCER AT THE 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM

BRIEF-CHMP Recommends EU Approval Of Roche's Kadcyla For Certain Early Breast Cancer Cases

* CHMP RECOMMENDS EU APPROVAL OF ROCHE’S KADCYLA FOR THE ADJUVANT TREATMENT OF PEOPLE WITH HER2-POSITIVE EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT TREATMENT Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up